Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-ACT Immunotherapy in Advanced Melanoma
NCT02327390Phase 1Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2015
- Primary completion
- Jul 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ex Vivo-Activated Lymph Node Lymphocytes in melanoma, sponsored by Case Comprehensive Cancer Center. Primary endpoint: Incidence of dose-limiting toxicity at 30 days. Started Mar 2015; status: terminated.
02
Drugs
Ex Vivo-Activated Lymph Node Lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02327390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327390.